All In Biotech

Drug Trial Radar · NCT01645332

Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus

Role of DLBS3233 in the Treatment of Subjects With New Onset of Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Oct 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

104

Actual

Start

Jul 2012

Primary completion

Aug 2014

Study completion Sep 2014

Sponsor

Lead sponsor
Dexa Medica GroupIndustry
Sponsor type
Industry
First posted
Jul 20, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-arm, double-blind, parallel, randomized, placebo-controlled clinical study, with 12 weeks of therapy to evaluate the efficacy and safety of DLBS3233 in improving metabolic control in newly diagnosed type-2-diabetic patients, as measured by A1c level, fasting and 2-hours post-prandial plasma glucose, fasting insulin level, HOMA-IR, HOMA-B, adiponectin level, lipid profile, and body weight.

Conditions

  • Type-2-diabetes Mellitus
  • New Onset

Interventions

  • Placebo of DLBS3233Drug

    Placebo of DLBS3233 once daily for 12 weeks

  • DLBS3233Drug

    100 mg DLBS3233 once daily for 12 weeks

  • Lifestyle modificationOther

    Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of A1c levelTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Division of Endocrinology, Department of Internal Medicine, Dr. Kariadi Hospital

    Semarang, Central Java, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.